Form 4 for ELVN Enliven Therapeutics, Inc.

Accepted 2021-07-16 00:00:00 ET · period of report 2021-07-16 · accession 0000947871-21-000775 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
I	2021-07-16	2021-07-16	ELVN	Bonita David P	Dir, 10%	P - Purchase	$6.00	+1.67M	1.67M	New	+$10.00M

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-07-16	P	A	1,666,666	$6.00	1,666,666	I See footnotes	—	—	(F1) These shares of the Issuer's common stock ("Shares") were purchased in the Company's underwritten public offering. (F2) The Shares are held of record by OrbiMed Partners Master Fund Limited ("OPM"). OrbiMed Capital LLC ("OrbiMed Capital"), a registered investment adviser under the Investment Advisers Act, acts as the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors LLC ("OrbiMed Advisors"). OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM. (F4) Each of the Reporting Person, OrbiMed Capital, OrbiMed Advisors, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.